Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Investing.com - BMO Capital lowered its price target on JBS SA (NYSE:JBS) to $17.00 from $19.00 on Tuesday, while maintaining an Outperform rating on the stock. The company, currently trading at $12.53 near its 52-week low of $12.37, appears undervalued according to InvestingPro analysis.
The price target reduction reflects BMO’s softer outlook for Pilgrim’s Pride Corporation (PPC) and weaker U.S. beef packer margins, which prompted the firm to lower its 2025 and 2026 estimates for JBS.
Despite the reduced price target, BMO remains more constructive on JBS compared to other protein industry peers, viewing the recent stock pullback as excessive.
BMO cited JBS’s diversified business model, which includes non-U.S. beef operations, as providing offsetting factors to the challenges in certain segments.
The firm noted that JBS currently trades at a discounted multiple of just over 6.5 times BMO’s 2026 EBITDA estimate, suggesting potential undervaluation despite the lowered outlook.
In other recent news, JBS NV reported its second-quarter earnings for 2025, revealing a notable earnings per share (EPS) of $0.50, which exceeded analyst projections of $0.39 by 28.17%. However, the company’s revenue did not meet expectations, coming in at $20.64 billion compared to the forecasted $21.47 billion. These developments have generated mixed reactions among investors. The earnings report highlights the company’s strong earnings performance despite the revenue shortfall. Analyst firms have not provided updates on stock upgrades or downgrades following this earnings release. The results underscore the importance of evaluating both earnings and revenue figures to understand the company’s financial health. These recent developments are crucial for investors keeping an eye on JBS NV.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.